The Private Equity Invasion of Your Cancer Care

What Happened

Over the past twenty years, private equity firms have quietly orchestrated one of the most consequential transformations in American healthcare. By systematically acquiring oncology practices, imaging centers, specialty pharmacies, and billing operations across the country, they have created sprawling corporate networks that now control significant portions of the nation’s cancer care infrastructure.

According to a new report from The Bull Moose Project, what was once a physician led system has increasingly shifted into the hands of financial firms driven primarily by profit targets rather than patient outcomes. Hundreds of oncology practices now operate under investor ownership.

The consolidation has been methodical and largely unnoticed by the public. Private equity groups identified cancer care as an attractive investment opportunity due to constant demand, predictable patient volumes, and Medicare reimbursement structures that often reward expensive drugs and complex procedures.

Wall Street investors targeted every aspect of cancer care delivery, from diagnostic imaging centers to specialty pharmacies that dispense chemotherapy drugs. This created vertically integrated systems where a single corporate entity controls multiple steps in the patient care journey. Medical professionals have increasingly been replaced by financial managers as the ultimate decision makers in treatment facilities across the country.

Why It Matters

The gradual shift from physician ownership to corporate control has fundamentally altered the incentives that drive medical decision making at every level of cancer care delivery.

Studies cited in the report indicate that private equity ownership in oncology is associated with higher price increases than any other medical specialty. At the same time, certain procedures show worse patient outcomes, including elevated complication rates and higher mortality in some cancer operations.

Global Ad Giants Are Buying the Pipes — This One’s Still Private

Global ad agencies are racing to buy the infrastructure — the data “pipes” and decision layers that control reach, relevance, and ROI. The consolidation wave is accelerating, and the smartest money is moving upstream.

RAD Intel already built that infrastructure, with a 14-year head start in AI. Its platform helps Fortune 1000 brands reach real customers with precision and speed. Fast Company calls RAD Intel “a groundbreaking step for the Creator Economy,” and recurring seven-figure contracts prove it’s working.

With $60M+ raised from 14,000+ investors, valuation up 5,000%+ in four years*, and sales contracts more than doubling in 2025, RAD Intel is scaling fast. Backed by Adobe, multiple Fidelity funds, and insiders from Google, Meta, and Amazon, the company has secured its Nasdaq ticker ($RADI) and positioned itself squarely in the path of the M&A surge.

Own shares at just $0.85 — this one’s still private.

👉 Lock in $0.85/share today

The pressure to maximize returns on investment means physicians working within these systems face mounting expectations to see more patients in less time. That can compromise the careful attention complex cancer cases require. Physicians may also face incentives to use more expensive therapies that do not always represent the optimal treatment path for individual patients.

These effects hit hardest in low income and rural communities, where corporate cost cutting measures and practice closures can leave patients with drastically reduced options. This further destabilizes access to essential services and worsens healthcare disparities that already affect vulnerable populations across the country.

The report also documents a troubling pattern of scandals involving private equity backed cancer providers. These include allegations of fraud, physician kickbacks, data breaches that compromise patient privacy, and bankruptcies that leave entire communities without cancer treatment facilities. Patients are then forced to travel long distances during their most vulnerable moments or forgo treatment altogether.

How It Affects You

The oncologist you see may now be employed by a corporate entity with quarterly earnings targets rather than operating as an independent practitioner focused solely on patient care. Treatment recommendations may be subtly influenced by corporate formularies that favor more expensive medications or procedures that generate higher revenue for the parent company.

For those living in rural areas or smaller communities, the oncology practice that has served your region for decades could be acquired and later closed if it fails to meet corporate profitability thresholds. This can leave patients facing the impossible choice between traveling hours for treatment or forgoing care entirely.

Wait times for appointments may increase as corporate efficiency mandates push physicians to maintain packed schedules. That leaves less time for careful discussion of treatment options and limits close monitoring of side effects. These gaps can mean the difference between effective care and dangerous complications.

Lawmakers and regulators are beginning to take notice. Antitrust enforcement is increasing, and new proposals would limit corporate control of medical practices. However, the private equity industry is pushing back aggressively and lobbying to block reforms. For patients, this leaves few protections when profit is prioritized over care during cancer treatment.

*Disclaimer: This is a paid advertisement for RAD Intel made pursuant to Regulation A+ offering and involves risk, including the possible loss of principal. The valuation is set by the Company and there is currently no public market for the Company's Common Stock. Nasdaq ticker “RADI” has been reserved by RAD Intel and any potential listing is subject to future regulatory approval and market conditions. Brand references reflect factual platform use, not endorsement. Investor references reflect factual individual or institutional participation and do not imply endorsement or sponsorship by the referenced companies. Please read the offering circular and related risks at invest.radintel.ai.